-
Mashup Score: 6Building the Evidence for Systemic Treatment in Desmoid Fibromatosis: Is a New Metronomic Regimen Another Layer in the Foundation? - 5 hour(s) ago
@Thalcin explains how a metronomic regimen for desmoid tumors fits in the current treatment landscape.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis - 6 hour(s) ago
PURPOSE Missed and delayed cancer diagnoses are common, harmful, and often preventable. Automated measures of quality of cancer diagnosis are lacking but could identify gaps and guide interventions. We developed and implemented a digital quality measure (dQM) of cancer emergency presentation (EP) using electronic health record databases of two health systems and characterized the measure’s association with missed opportunities for diagnosis (MODs) and mortality. METHODS On the basis of literature and expert input, we defined EP as a new cancer diagnosis within 30 days after emergency department or inpatient visit. We identified EPs for lung cancer and colorectal cancer (CRC) in the Department of Veterans Affairs (VA) and Geisinger from 2016 to 2020. We validated measure accuracy and identified preceding MODs through standardized chart review of 100 records per cancer per health system. Using VA’s longitudinal encounter and mortality data, we applied logistic regression to assess EP’s a
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets - 8 hour(s) ago
PURPOSE The highly aggressive undifferentiated sarcomatoid carcinoma (USC) subtype of pancreatic ductal adenocarcinoma (PDAC) remains poorly characterized because of its rarity. Previous case reports suggest that immune checkpoint inhibitors could be a promising treatment strategy, but the prevalence of established predictive biomarkers of response is largely unknown. The objective of this study was to leverage comprehensive genomic profiling of USC PDAC tumors to determine the prevalence of biomarkers associated with potential response to targeted therapies. METHODS USC tumors (n = 20) underwent central pathology review by a board-certified gastrointestinal pathologist to confirm the diagnosis. These samples were compared with non-USC PDAC tumors (N = 5,562). Retrospective analysis of DNA and RNA next-generation sequencing data was performed. RESULTS USC PDACs were more frequently PD-L1+ by immunohistochemistry than non-USC PDAC (63% v 16%, respectively, P < .001). Furthermore, USC PD
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
The stream of publications and progress continues! Out today in @JCOPO_ASCO: Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets https://t.co/nFZyj2eoL1 Another one from @fabermdphd and @carisls GI Onc group. https://t.co/7iJcCkIauv
-
-
Mashup Score: 51
TPS9605 Background: Adjuvant treatment with anti-PD1 therapy improves the recurrence free survival (RFS) in resectable stage III melanoma. The Checkmate-238 and KEYNOTE-054 trials respectively reported a 4-year RFS of 52.5% for adjuvant nivolumab and a 3-year RFS of 63.7% for adjuvant pembrolizumab. Despite these improved outcomes, a considerable proportion of patients have a relapse in the years after therapeutic lymph node dissection (TLND). The OpACIN trial showed that neoadjuvant treatment with nivolumab (NIVO) plus ipilimumab (IPI) is feasible and induces a stronger and broader T-cell response. The subsequent OpACIN-neo trial identified 2 cycles of NIVO 3mg/kg + IPI 1mg/kg as a neoadjuvant dosing scheme with decreased toxicity and preserved high pathologic response rates (77%), which was confirmed in the PRADO trial. A favorable 2-year RFS (83,6%) was achieved in the overall OpACIN-neo population, although patients with a pathological partial or non-response have a worse prognosis
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary #ASCO24 . Shorter periods of therapy in responders (neoadjuvant alone) is an important question. Neoadjuvant nivo didn’t work in RCC (PROSPER). PACIFIC2 struggled in lung https://t.co/SFqWIUjKlI https://t.co/Eu2o2lQx65
-
-
Mashup Score: 1
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process. The systematic review focused on guidelines, systematic reviews and meta-analyses, randomized controlled trials, and case series published from 2000 through 2017. Results The systematic review identified 204 eligible publications. Much of the evidence consisted of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quali
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
PURPOSE Recent evidence has shown that higher tumor mutational burden strongly correlates with an increased risk of immune-related adverse events (irAEs). By using an integrated multiomics approach, we further studied the association between relevant tumor immune microenvironment (TIME) features and irAEs. METHODS Leveraging the US Food and Drug Administration Adverse Event Reporting System, we extracted cases of suspected irAEs to calculate the reporting odds ratios (RORs) of irAEs for cancers treated with immune checkpoint inhibitors (ICIs). TIME features for 32 cancer types were calculated on the basis of the cancer genomic atlas cohorts and indirectly correlated with each cancer’s ROR for irAEs. A separate ICI-treated cohort of non–small-cell lung cancer (NSCLC) was used to evaluate the correlation between tissue-based immune markers (CD8+, PD-1/L1+, FOXP3+, tumor-infiltrating lymphocytes [TILs]) and irAE occurrence. RESULTS The analysis of 32 cancers and 33 TIME features demonstra
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13Failing Forward in Peripheral T-Cell Lymphoma - 16 hour(s) ago
Peripheral T-cell lymphomas (PTCLs) are an uncommon, heterogeneous group of non-Hodgkin lymphomas. The most frequent subtypes are T-follicular helper (TFH) cell, peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), and systemic anaplastic large cell lymphoma (sALCL). Standardly used frontline therapeutic strategies are borrowed from other aggressive lymphomas with historic 5-year overall survivals (OSs) of 30%-40%. 1, 2 In the landmark ECHELON-2 study, brentuximab vedotin (BV) in combination
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual - 16 hour(s) ago
Use of screening logs to document enrollment barriers at the local level can facilitate development of strategies to enhance accrual.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Purpose Children have historically been excluded from first-in-human studies of promising new cancer drugs and later phase adult clinical trials. Delays in evaluation may result in off-label use without dosing information as the only access to new drugs. A multistakeholder workshop was convened in May 2016 by ASCO and Friends of Cancer Research to identify opportunities for when it would be scientifically appropriate to expand trial eligibility to include children younger than age 18 years in first-in-human and other adult cancer clinical trials. Methods This group convened experts from academia, government, and industry to review barriers to enrolling children and adolescents in oncology clinical trials. We evaluated the historical context, published literature, regulatory considerations, and myriad risks and benefits associated with lowering the age of enrollment on oncology clinical trials. Results We conclude that many of the historical concerns about including children early in on
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
TPS8055 Background: Pts with transplant-ineligible NDMM require therapies which prolong survival and improve quality of life. The combination of VRd significantly improves progression-free (PFS) and overall survival compared with Rd in NDMM, and has an acceptable safety profile. Combining VRd with a monoclonal antibody (mAb) may further improve efficacy. Isatuximab (ISA) is an anti-CD38 mAb that demonstrates antitumor and immunomodulatory activities with strong potentiation when combined with V and R in MM xenograft models. Here we describe a Phase III, randomized, open-label, multicenter study (NCT03319667; IMROZ), evaluating clinical benefit of ISA plus VRd vs VRd in pts with transplant-ineligible NDMM. Methods: Approximately 440 adult pts with symptomatic MM (International Myeloma Working Group [IMWG] criteria) will be randomly assigned, according to Revised International Staging System criteria (I or II vs III vs unknown) and age ( < 70 vs ≥70 years), in a 3:2 ratio to ISA (10 mg/k
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Building the Evidence for Systemic Treatment in Desmoid Fibromatosis: Is a New Metronomic Regimen Another Layer in the Foundation? | JCO Global Oncology https://t.co/tPCUvPlwti Grateful to @JCOGO_ASCO for the invitation to write this editorial. Congratulations to the authors!